We Will Cure published a roadmap of longevity biotechnology clinical trials through 2027

We Will Cure published a roadmap of longevity biotechnology clinical trials through 2027

On August 25, the editorial project We Will Cure compared programs that have begun human studies, reported initial data, or are preparing for the next stage. By the end of 2027, these programs will address different questions: whether people can tolerate the intervention, whether it affects the targeted process, and whether there is sufficient reason to expand the trial.

Companies test hypotheses about the biology of aging through specific diseases and measurable outcomes, as an earlier analysis of the regulatory pathway explained. This roadmap therefore compares programs targeting different mechanisms of aging according to one criterion: the next question that each program can answer in humans.

The roadmap includes partial reprogramming, which aims to restore more youthful patterns of gene activity in cells, senolytics, which remove accumulated senescent cells, and drugs targeting autophagy, the cellular process that disposes of worn components, as well as metabolism and chronic inflammation. Early studies answer a sequence of questions: whether people can tolerate the drug, whether it changes the intended biological process, and whether that change is large enough to justify a larger trial.

BioAge has already reported an early signal for BGE-102. According to the company, hsCRP, a blood marker of inflammation, decreased in participants with obesity and elevated inflammation. The ClinicalTrials.gov registry is already recruiting participants for a 12-week placebo-controlled comparison in people with obesity and cardiovascular risk factors. The placebo is a tablet containing no active substance. The next trial will assess the same marker in a predefined group over a specified period.

Cambrian Bio reported a different stage of evidence for ATX-304. Over eight weeks, 23 adults with obesity and prediabetes showed changes in liver fat, fat surrounding the internal organs, triglyceride levels, and resting energy expenditure. The company plans to focus subsequent studies on muscle function, fat metabolism, and weight loss.

Life Biosciences’ ER-100 gene therapy is currently undergoing its first human trial in people with optic nerve disorders. The study is evaluating safety and tolerability, with visual function assessed as an additional outcome. The therapy delivers instructions for three proteins that regulate gene activity to retinal cells: OCT4, SOX2, and KLF4. Retro Biosciences is already evaluating RTR242, an oral drug that activates autophagy, in its first human trial. The company also plans to administer its other drugs to humans for the first time in 2026–2027.

By the end of 2027, the roadmap will contain answers of different scope: whether the intervention can be tolerated safely, whether it changes the targeted process in humans, and whether there is sufficient reason to proceed to a larger trial. The early programs already differ in which of these three questions they can address.